Memorial Sloan-Kettering Cancer Center (MSKCC) Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental Biology, Genomic Integrity, and Molecular Structure);Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the ten research programs depends on services provided by 34 core facilities, 19 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs;therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquiry and to support the core facilities which have grown to support the needs of the research enterprise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-45
Application #
7764725
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2012-12-31
Budget Start
2010-04-26
Budget End
2010-12-31
Support Year
45
Fiscal Year
2010
Total Cost
$13,879,526
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Antonescu, Cristina R; Agaram, Narasimhan P; Sung, Yun-Shao et al. (2018) A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions. Am J Surg Pathol 42:553-560
Baumann, Michael H; Majumdar, Susruta; Le Rouzic, Valerie et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134:101-107
Escalon, Joanna G; Harrington, Kate A; Plodkowski, Andrew J et al. (2018) Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography? J Comput Assist Tomogr 42:601-606
Rosen, Lauren E; Karrison, Theodore; Ananthanarayanan, Vijayalakshmi et al. (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598-606
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Lambertini, Matteo; Campbell, Christine; Bines, José et al. (2018) Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst :
Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60
Wang, Hongmei; Deng, Jikui; Tang, Yi-Wei (2018) Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test. Expert Rev Mol Diagn 18:403-409
Tseng, Jill H; Aloisi, Alessia; Sonoda, Yukio et al. (2018) Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer. Int J Gynecol Cancer 28:1350-1359
Pronier, Elodie; Bowman, Robert L; Ahn, Jihae et al. (2018) Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood 132:1265-1278

Showing the most recent 10 out of 8799 publications